<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00778882</url>
  </required_header>
  <id_info>
    <org_study_id>VM106-KR-01</org_study_id>
    <nct_id>NCT00778882</nct_id>
  </id_info>
  <brief_title>Gene Therapy for Chronic Granulomatous Disease in Korea</brief_title>
  <official_title>An Open-label, Uncontrolled, Single Center, Phase I/II Trial to Assess the Safety and Efficacy of Autologous Hematopoietic Stem Cells Transduced With MT-gp91 Retroviral Vector in gp91 Defective Chronic Granulomatous Disease Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ViroMed Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ViroMed Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of administration of
      autologous hematopoietic stem cells transduced with MT-gp91 retroviral vector for patients
      with X-linked chronic granulomatous disease.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of adverse events through 1 year</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>RCR, insertional mutagenesis, immune response against normal gp91 protein</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and efficacy of fludarabine/busulfan conditioning</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional reconstitution of respiratory burst</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of vector-positive cells</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Chronic Granulomatous Disease</condition>
  <arm_group>
    <arm_group_label>VM106</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VM106</intervention_name>
    <description>Autologous hematopoietic stem cells with MT-gp91 retroviral vector</description>
    <arm_group_label>VM106</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  gp91 defective male patients with chronic granulomatous disease: confirmed by DHR

          -  Weigh greater than or equal to 15 kg

          -  History of severe infections: more than 2 times

          -  Performance status: ECOG 0-2

          -  Patients must be free of significant functional deficits in major organs, but the
             following eligibility criteria may be modified in individual cases.

               -  Heart: a shortening fraction &gt; 28%; QTc interval &lt; 0.44

               -  Liver: total bilirubin &lt; 2 × upper limit of normal; ALT &lt; 3 × upper limit of
                  normal; AST &lt; 3 x upper limit of normal

               -  Kidney: creatine &lt; 2 x normal

               -  Blood: WBC &gt; 2,500/uL; platelet &gt; 100,000/uL; hematocrit &gt; 26%

          -  Written informed consent obtained from patient (or guardian if patients age &lt; 19)

        Exclusion Criteria:

          -  Presence of a HLA-matched sibling for stem cell donation

          -  Evidence or history of malignant tumor

          -  Presence of a severe infection

          -  Presence of an active tuberculosis

          -  Uncorrectable electrolyte, Ca, P

          -  Unable to comply with the protocol or to cooperate fully with the Investigator or site
             personnel
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joong Gon Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2008</study_first_submitted>
  <study_first_submitted_qc>October 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2008</study_first_posted>
  <last_update_submitted>February 10, 2016</last_update_submitted>
  <last_update_submitted_qc>February 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Granulomatous Disease</keyword>
  <keyword>Retroviral Vector</keyword>
  <keyword>Gene Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Granuloma</mesh_term>
    <mesh_term>Granulomatous Disease, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

